Chronic fatigue syndrome as a delayed reaction to chronic low-dose organophosphate exposure

Journal of Nutritional and Environmental Medicine

Volumn 6, Issue 4, 1996, Pages 341-350

  Behan, Peter O ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

5 hydroxytryptamine; Brain steroid receptors; Buspirone; Chronic fatigue syndrome; Dexamethasone; Growth hormone; Hypothalamus; Neurobehavioural syndrome; Organophosphates; Pyridostigmine

Indexed keywords

BUSPIRONE; ORGANOPHOSPHATE INSECTICIDE; PROLACTIN;

ADULT; AGRICULTURAL WORKER; ARTICLE; BLOOD SAMPLING; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; NEUROENDOCRINOLOGY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SYMPTOM; UNITED KINGDOM;

EID: 0030480943     PISSN: 13590847     EISSN: None     Source Type: Journal    
DOI: 10.3109/13590849609007262     Document Type: Article

References (30)

1. Fukuda K, Straus SE, Hickie I et al. and the International Chronic Fatigue Syndrome Study Group. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994; 121: 953-59.
2. Bakheit AMO, Behan PO, Watson WS et al. Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome. Acta Neurol Scand 1993; 87: 234-8.
3. Bakheit AMO, Behan PO, Dinan TG et al. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ 1992; 304: 1010-2.
4. Gershon S, Shaw FH. Psychiatric sequelae of chronic exposure to organophosphorous insecticides. Lancet 1961; 24 June: 1371-1
5. Rosenstock L, Keifer M, Daniell W et al. Chronic central nervous system effects of acute organophosphate pesticide intoxication. Lancet 1991; 338: 223-7.
6. Sharp DS, Eskenazi B, Harrison R et al. Delayed health hazards of pesticide exposure. Ann Rev Publ Health 1986; 7: 441-71.
7. Behan PO, Haniffah BAG. Chronic fatigue syndrome: a possible delayed hazard of pesticide exposure. Clin Infect Dis 1994; 18 (suppl. 1): S54.
8. Murray VS, Wiseman HM, Dawling S et al. Health effects of organophosphate sheep dips. BMJ 1992; 305: 1090.
9. Newcombe DS. Immune surveillance, organophosphorous exposure and lymphomagenesis. Lancet 1992; 339: 539-41.
10. Zahm SH, Blair A. Pesticides and non-Hodgkin's lymphoma. Cancer Res 1992; 52 (suppl.): 5485-8.
11. Wigle DT, Semenciw RM, Wilkins K et al. Mortality study of Canadian male farm operators: non-Hodgkin's lymphoma mortality and agricultural practices in Saskatchewan. J Natl Cancer Inst 1990; 7: 575-82.
12. Straus SE, Dale JK, Wright R et al. Allergy and the chronic fatigue syndrome. J Allergy Clin Immunol 1988; 81: 791-5.
13. Morrison LJA, Behan WMH, Behan PO. Changes in natural killer cell phenotype in patients with post-viral fatigue syndrome. Clin Exp Immunol 1991; 83: 441-6.
14. Tirelli U, Marotta G, Improta S et al. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994; 40: 601-8.
15. Landay AL, Jessop C, Lennette ET et al. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991; 338: 707-12.
16. Buchwald D, Cheney PR, Peterson DL et al. A chronic illness characterized by fatigue, neurological and immunologic disorders, and active human herpes virus type 6 infection. Ann Intern Med 1992; 166: 103-13.
17. Nakaya T, Takahash H, Nakamura Y et al. Demonstration of Borna disease virus RNA in peripheral blood mononuclear cells derived from Japanese patients with chronic fatigue syndrome. FEBS Lett 1996; 378: 145-9.
18. Gow JW, Behan WMH, de la Torre JC et al. Borna disease virus and chronic fatigue syndrome. In: Proceedings of First World Congress on Chronic Fatigue Syndrome and Related Disorders, Brussels, 1995.
19. Majeed T, Behan PO. Clinical overview of chronic fatigue syndrome. EOS 1995; 8-14.
20. Charig EM, Anderson IM, Robinson JM et al. L-Tryptophan & prolactin release. Evidence for interaction between 5-HT1 & 5-HT2 receptors. Hum Psychol Pharmacol 1986; 1: 193-7.
21. Cleare AJ, Bearn J, McGregor A et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Dis 1995; 34: 283-9.
22. Janowsky DS, Davis JM. Psychological effects of cholinomimetic agents. In: Brain Acetylcholine and Neurophychiatric Disease. New York: Plenum Press, 1979, pp. 3-14.
23. Casaneuva FF, Belti R, Cella SG et al. Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog. Acta Endocrinol 1983; 103: 15-20.
24. Majeed T. Neuroendocrine alteration in chronic fatigue syndrome. PhD thesis, Glasgow University, 1996.
25. Bowers MB, Boodman E, Sim VM. Some behavioural changes in man following anti-cholinesterase administration. J Nerv Men Dis 1964; 138: 383-9.
26. Nakagawa K, Istizuka T, Ohara T et al. Dichotomic action of glucocorticoids on growth hormone secretion. Acta Endocrinol (Copenh) 1987; 116: 165-71.
27. Majeed T, Dinan TG, Thakore J et al. Defective dexamethasone induced growth hormone release in CFS: evidence of glucocorticoid receptor resistance and lack of plasticity? J Irish Coll Phys & Surg 1995; 24: 20-24.
28. Blisard KS, Kornfeld M, McFeeley P et al. The investigation of alleged insecticide toxicity: a case involving chlordane exposure, multiple sclerosis and peripheral neuropathy. J Forensic Sci 1986; 31: 1499-504.
29. Krupp LB, Alvarez LA, LaRocca NG et al. Fatigue in multiple sclerosis. Arch Neurol 1988; 45: 435-7.
30. Rosenberg GA, Appenzeller O. Amantadine, fatigue and multiple sclerosis. Arch Neurol 1988; 45: 1104-6.